Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.87 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | TMIGD3 | P0DMS9 | 10/20 | 0.85 |
| ▸ | HTR2C | P28335 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22359740 | 0.93 | ADORA3 (1.00) | ADORA3SLC6A3SLC6A2CYP2D6TMIGD3 | |
| SCHEMBL16774147 | 0.93 | ADORA3 (1.00) | ADORA3SLC6A3SLC6A2CYP2D6TMIGD3 | |
| SCHEMBL20121272 | 0.91 | TMIGD3 (0.73) | ADORA3SLC6A3SLC6A2CYP2D6TMIGD3 | |
| SCHEMBL18352471 | 0.91 | TMIGD3 (0.73) | ADORA3SLC6A3SLC6A2CYP2D6TMIGD3 | |
| SCHEMBL18352432 | 0.86 | ADORA3 (0.86) | ADORA3SLC6A3SLC6A2CYP2D6TMIGD3 | |
| SCHEMBL18352467 | 0.85 | ADORA3 (0.84) | ADORA3ADORA2A | |
| SCHEMBL11301939 | 0.84 | ADORA3 (0.85) | ADORA3TMIGD3ADORA2A | |
| SCHEMBL11299477 | 0.83 | ADORA3 (0.87) | ADORA3SLC6A3SLC6A2KCNH2ADORA2A | |
| SCHEMBL11299612 | 0.83 | ADORA3 (0.76) | ADORA3SLC6A3SLC6A2KCNH2ADORA2A | |
| SCHEMBL24615115 | 0.83 | ADORA3 (1.00) | ADORA3SLC6A3SLC6A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002007-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002007-A1 | A3 ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885SLC6A3 493/4885SLC6A2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.